← Back to Search

Procedure

Laser Resurfacing for Skin Rejuvenation

N/A
Waitlist Available
Led By Jeffrey Travers, MD, PhD
Research Sponsored by Wright State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Planning to undergo abdominoplasty surgery
Minimum amount of skin to be removed is 50 x 20cm
Must not have
Medical history of not well-controlled diabetes
History of pathologically abnormal wound healing such as keloidal scars
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks prior to skin removal and 1 week prior to skin removal
Awards & highlights

Summary

This trial aims to understand where the cells that help rejuvenate skin after laser treatment come from. The study will focus on fibroblasts present in geriatric skin treated with Fractionated Laser Resurf

Who is the study for?
This trial is for individuals scheduled for abdominoplasty who may benefit from Fractionated Laser Resurfacing (FLR) to potentially protect against skin cancer. The study focuses on understanding how FLR treatment rejuvenates the skin by examining fibroblasts, cells that help repair damaged skin.
What is being tested?
The trial investigates the origin of fibroblasts after Fractionated Laser Resurfacing treatment in patients undergoing abdominoplasty. It aims to understand how these cells contribute to a youthful UVB response and possibly prevent skin cancer.
What are the potential side effects?
While specific side effects are not listed, typical reactions to laser treatments can include redness, swelling, itching, and temporary discomfort at the site of application. More serious side effects might occur but are not detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am planning to have a tummy tuck surgery.
Select...
I need surgery to remove a skin area of at least 50 x 20cm.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My diabetes is not well-controlled.
Select...
I have a history of abnormal scar formation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks prior to skin removal and 1 week prior to skin removal
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks prior to skin removal and 1 week prior to skin removal for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.
Secondary study objectives
To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fractionated Laser ResurfacingExperimental Treatment1 Intervention
At 14 days prior to scheduled surgery a 5x5cm square on the left abdomen within the region of skin to be excised and treated with fractionated laser resurfacing. Then at 7 days prior to scheduled surgery a 5 cm diameter circle on the right abdomen within the region of skin to be excised, at least 10 cm away from the square, is treated with fractionated laser resurfacing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fractionated Laser Resurfacing
2007
N/A
~20

Find a Location

Who is running the clinical trial?

Wright State UniversityLead Sponsor
44 Previous Clinical Trials
54,946 Total Patients Enrolled
Jeffrey Travers, MD, PhDPrincipal InvestigatorWright State University
1 Previous Clinical Trials
80 Total Patients Enrolled
~8 spots leftby Dec 2028